Meeting
2022 ASCO Genitourinary Cancers Symposium
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.
Authors
Meredith McKean
Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN
Meredith McKean , Matthew H. Carabasi , Mark N. Stein , Michael Thomas Schweizer , Jason J. Luke , Vivek Narayan , Rahul Atul Parikh , Russell Kent Pachynski , Jingsong Zhang , Vijay Gopal Reddy Peddareddigari , James Winnberg , Amy Roberts , Jamie Rosen , Pam Hufner , Whitney Gladney , Thomas J. Fountaine , Karen Chagin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04227275
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 94)
DOI
10.1200/JCO.2022.40.6_suppl.094
Abstract #
94
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
First Author: Vivek Narayan
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun
Poster
2018 Genitourinary Cancers Symposium
Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa